Expert Interview
Discussing Amgen's sotorasib, in KRAS G12C-mutated mCRC and the results from the P3 CodeBreak 300 study presented at ESMO 2023
Ticker(s): AMGNInstitution: CIMCA
- Medical Oncologist and Director of the Centro de Investigación y Manejo del Cáncer (CIMCA) in San José, Costa Rica.
- Treats 5 new patients every month with mCRC, with 2.5% of them being KRAS G12C-mutated mCRC.
- Research interest in thoracic oncology and is the lead investigator for several international clinical trials at CIMCA.
Can you discuss your current clinical practice and estimate roughly how many patients you treat for KRAS G12C-mutated mCRC ?
Added By: sara_adminHow does the updated data from the P3 CodeBreak 300 study compare to your clinical experience with the current SOC?
Added By: sara_adminOn a level from 1-10 how would you rate your excitement about sotorasib and the results from the CodeBreaK 300 phase III study?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
